The US genomic biomarker market is estimated to grow significantly at a CAGR of around 15.6% during the forecast period. Factors that are contributing significantly to the market growth include the presence of well-developed healthcare infrastructure, increasing healthcare R&D investments, high healthcare expenditure and others. Moreover, the market growth is attributed to the rising prevalence of cancer, CVDs, and chronic diseases. The rising number of cancer patients is considered to be one of the major factors that are driving the growth of the market in the US.
The US genomic biomarker market is segmented on the basis of application and end-user. On the basis of application, the market is segmented into oncology, cardiology, neurology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. A genomic biomarker can detect various types of diseases. However, most of the research institutes are majorly focused on oncology diagnosis and therapeutics. The genomic biomarker is widely used for the diagnosis of various types of cancer across the globe. On the basis of end-user, the market is segmented into hospitals and diagnostic.
The major players in the North American genomic biomarker market include Agilent Technologies, Inc., Qiagen N.V., Illumina, Inc., Myriad Genetics, Inc., Thermo Fischer Scientific, Inc., Genomic Health Inc., Bio-Rad Laboratories Inc., and Hologic, Inc. These players have been focusing on new product developments as well as upgrading their product portfolios to stay competitive in the market. Product launch, geographic expansion, and mergers and acquisitions are some of the key strategies adopted by the market players in the past few years. For instance, In July 2017, Agilent Technologies, Inc. introduced Agilent Sure select which is advanced high sensitivity Next-Generation Sequencing (NGS) target enrichment solution for research, sequence DNA from formalin-fixed paraffin-embedded samples.
The Report Covers
- Comprehensive research methodology of the US Genomic Biomarker Market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the US Genomic Biomarker Market.
- Insights about market determinants which are stimulating the US Genomic Biomarker Market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Key Topics Covered:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
5. Market Segmentation
5.1. US Genomic Biomarker Market by Application
5.2. US Genomic Biomarker Market by End-User
5.2.2. Diagnostic & Research Laboratories
6. Company Profiles
6.1. Abbott Laboratories Inc.
6.2. Agilent Technologies, Inc.
6.3. Banyan Biomarkers, Inc.
6.4. Beckman Coulter Inc.
6.5. Becton, Dickson and Co.
6.6. Bio-Rad Laboratories, Inc.
6.7. Celgene Corp.
6.8. Cofactor Genomics, Inc.
6.9. Empire Genomics, LLC
6.10. Enzo Life Sciences, Inc.
6.11. Foundation Medicine, Inc.
6.12. Genomic Health, Inc.
6.13. Hologic, Inc.
6.14. Human Longevity, Inc.
6.15. Illumina, Inc.
6.16. Insight Genetics, Inc.
6.17. Inova Diagnostics, Inc.
6.18. Luminex Corp.
6.19. Myriad Genetics, Inc.
6.20. NanoString Technologies, Inc.
6.21. NeoGenomics, Inc.
6.22. OriGene Technologies, Inc.
6.23. Pacific Biomarker Inc.
6.24. Pfizer, Inc.
6.25. Pliant Therapeutics, Inc.
6.26. Quest Diagnostics Inc.
6.27. Response Biomedical Corp.
6.28. Signosis Inc.
6.29. Thermo Fisher Scientific Inc.
6.30. Verge Genomics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/p8zkjz